Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
16.23
+0.14 (+0.87%)
Streaming Delayed Price
Updated: 4:00 PM EST, Mar 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
28
29
30
31
32
33
34
35
Next >
Sarepta Therapeutics (SRPT) Q4 2022 Earnings Call Transcript
↗
February 28, 2023
SRPT earnings call for the period ending December 31, 2022.
Via
The Motley Fool
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 28, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Novavax Stock Down On Concern Over Whether The Company Can Continue
↗
February 28, 2023
Novavax warns that it may not be able to continue as a company.
Via
Talk Markets
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
February 28, 2023
Via
Benzinga
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
February 28, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Expert Ratings for Sarepta Therapeutics
↗
February 15, 2023
Via
Benzinga
9 Analysts Have This to Say About Sarepta Therapeutics
↗
January 20, 2023
Via
Benzinga
BTIG Maintains Buy Rating for Sarepta Therapeutics: Here's What You Need To Know
↗
December 22, 2022
Via
Benzinga
Analyst Ratings for Sarepta Therapeutics
↗
November 03, 2022
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:
Via
Benzinga
Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program
February 28, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For February 28, 2023
↗
February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
Via
Benzinga
Sarepta Therapeutics (SRPT) Q3 2022 Earnings Call Transcript
↗
November 03, 2022
SRPT earnings call for the period ending September 30, 2022.
Via
The Motley Fool
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results
February 21, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
February 17, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
3 Gene Editing Stocks With the Best Long-Term Potential
↗
January 25, 2023
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space
Via
InvestorPlace
7 Biotech Stocks That Will Make You Rich in 10 Years
↗
January 18, 2023
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.
Via
InvestorPlace
7 Analysts Have This to Say About Sarepta Therapeutics
↗
October 13, 2022
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:
Via
Benzinga
2 Under-the-Radar Biotech Stocks to Buy in 2023
↗
January 06, 2023
These biotechnology stocks are pushing ahead with promising innovations.
Via
The Motley Fool
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
January 05, 2023
From
Catalent, Inc.
Via
Business Wire
2 Top Healthcare Stocks to Buy for the Long Haul
↗
December 09, 2022
These two companies are just getting started.
Via
The Motley Fool
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
↗
December 02, 2022
The S&P 500 is fighting for its 200-day, a critical level for the uptrend.
Via
Investor's Business Daily
Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy
↗
November 28, 2022
Sarepta Therapeutic is nearing the finish line with its Duchenne muscular dystrophy gene therapy.
Via
Investor's Business Daily
3 Unstoppable Stocks That Could Double in 5 Years
↗
October 29, 2022
The opportunities for these innovators are tremendous.
Via
The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2022
↗
October 19, 2022
These two drugmakers are growing in prominence.
Via
The Motley Fool
Apple To $177? Plus This Analyst Slashes PT On Opendoor Technologies By About 71%
↗
October 17, 2022
Morgan Stanley cut Apple Inc. (NASDAQ: AAPL) price target from $180 to $177. Apple shares rose 1.1% to $139.95 in pre-market trading.
Via
Benzinga
Is Pfizer Stock Still Worth Buying After the Pandemic?
October 12, 2022
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations.
Via
MarketBeat
Earnings Scheduled For November 2, 2022
↗
November 02, 2022
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter.
Via
Benzinga
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
September 29, 2022
Via
AB Newswire
A Trio of Q3 Winners With Room to Run
September 29, 2022
It's those rare bright spots in a dim market that can be the best places to hide. Here are three Q3 outperformers that still have good upside.
Via
MarketBeat
Topics
Economy
Stocks
PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst
↗
September 28, 2022
Via
Benzinga
< Previous
1
2
...
28
29
30
31
32
33
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
